A research group led by Professor Wei Li from the Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Toho University, in collaboration with the Duke University Medical Center in the ...

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved an expanded label for Iluvien (fluocinolone acetonide ...

Analyst Price Forecast Suggests 29.28% Upside As of March 4, 2025, the average one-year price target for ANI Pharmaceuticals is $80.75/share. The forecasts range from a low of $62.62 to a high of ...

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals ANIP over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an ...

Jefferies initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $80 price target The firm expects continued momentum for the shares, driven primarily by Cortrophin Gel and generics.

March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ...

J.P. Morgan on Wednesday launched its coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with an Overweight recommendation and a year-end price target of $85 per share, citing the specialty pharma ...

Highlights,Focus on branded and generic prescription products across multiple regions.,Multifaceted manufacturing capabilities that include oral solids, semi-solids, liquids, and more.,Notable ...

JPMorgan initiated coverage of ANI Pharmaceuticals (ANIP) with an Overweight rating and $85 price target ANI is a specialty pharmaceuticals company with a “well-positioned and durable ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...